Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-089304
Filing Date
2024-08-01
Accepted
2024-08-01 16:15:25
Documents
66
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atha-20240630.htm   iXBRL 10-Q 2196383
2 EX-31.1 atha-ex31_1.htm EX-31.1 15447
3 EX-31.2 atha-ex31_2.htm EX-31.2 15352
4 EX-32.1 atha-ex32_1.htm EX-32.1 8744
5 EX-32.2 atha-ex32_2.htm EX-32.2 7851
6 GRAPHIC img106167332_0.jpg GRAPHIC 89700
  Complete submission text file 0000950170-24-089304.txt   7644289

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atha-20240630.xsd EX-101.SCH 937645
68 EXTRACTED XBRL INSTANCE DOCUMENT atha-20240630_htm.xml XML 1126142
Mailing Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011
Business Address 18706 NORTH CREEK PARKWAY, SUITE 104 BOTHELL WA 98011 (425) 620-8501
Athira Pharma, Inc. (Filer) CIK: 0001620463 (see all company filings)

EIN.: 453368487 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39503 | Film No.: 241166889
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)